Ping Dai | Cancer Therapy | Best Researcher Award

Dr. Ping Dai | Cancer Therapy | Best Researcher Award

Tongji University | China

AUTHOR PROFILE

SCOPUS ID

🏥DR. PING DAI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Ping Dai’s journey in medicine began with a Diploma of Higher Education in Clinical Medicine from Harbin University, followed by a Bachelor’s degree at Qiqihar Medical University. She excelled further with an Outstanding Master’s Degree in Oncology from Shihezi University, and culminated her academic path with a Doctorate in Molecular Radiation Oncology (Dr. Med, Magna Cum Laude) from the prestigious Heidelberg University in Germany—underscoring a profound commitment to academic excellence and clinical innovation.

🩺PROFESSIONAL ENDEAVORS

With over a decade of clinical and research experience, Dr. Dai currently serves as Assistant Director at the Shanghai Fourth People’s Hospital Affiliated to Tongji University. Her career spans multiple critical roles—oncologist, clinical researcher, and international doctoral candidate at the German Cancer Research Centre (DKFZ)—fusing global perspectives with localized healthcare innovation.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BIOMARKERS  IN CANCER THERAPY

Dr. Dai’s research centers on radiation oncology, immunotherapy-related thyroid dysfunction, and tumor treating fields (TTFields). Notably, her recent studies explore PD-1/PD-L1 inhibitor-induced thyroid dysfunction as a biomarker for efficacy in advanced lung cancer therapy, published in BMC Cancer and Heliyon. She also leads groundbreaking simulation research on electrodynamic tumor interactions, merging clinical oncology with bioengineering insight.

🌍IMPACT AND INFLUENCE

Dr. Dai’s cross-continental experience—from China to Germany—bridges Eastern and Western oncology practices. Her insights contribute to both clinical protocol improvements and space-radiation biology, collaborating with institutions such as the European Space Agency and Heidelberg Ion Beam Therapy Center. She plays a vital role in shaping translational cancer science and space medicine.

🏆ACADEMIC CITES, ACCOLADES AND RECOGNITION

  • Lead or corresponding author in high-impact journals: Cancer Letters (IF 9.7), APL Bioengineering (IF 6.6), and Frontiers in Oncology.

  • Honored with Outstanding Master’s Graduate award.

  • Latin honors “Magna Cum Laude” for doctoral studies in Germany.

  • Recognized as equal-first author and corresponding author in multiple prestigious publications.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Dai is establishing a legacy of translational research at the intersection of radiation therapy, immunology, and biomarker discovery. Her future pursuits aim to:

  • Advance predictive markers for immunotherapy outcomes.

  • Explore MSC-based interventions against radiation-induced myelotoxicity.

  • Lead multinational clinical collaborations in cancer therapy and space radiation countermeasures.

🧬CONCLUSION

Dr. Ping Dai is an emerging force in molecular oncology and translational medicine. With a rich academic foundation, strong clinical acumen, and a forward-thinking research vision, she is contributing impactful solutions to global oncology and radiobiology challenges.

📊🔬NOTABLE PUBLICATION:

Thyroid dysfunction as a predictor of PD-1/PD-L1 inhibitor efficacy in advanced lung cancer

Authors: Yanling Wang, Xiaoping Ma, Jia Ma, Jing Li, Zhiyi Lin, Wei Gao, Ping Gong, Ping Dai
Journal: BMC Cancer
Year: 2025

Comprehensive Simulations of Intracellular Electric Fields during Exposure to Tumor Treating Fields (TTFields)

Authors: Kaida Liu, Ping Dai, Zirong Liu, Haohan Fang, Xing Li, Wei Gao
Journal: Frontiers in Oncology
Year: 2025 (Accepted)

Electrodynamic Interaction between Tumor Treating Fields and Microtubule Electrophysiological Activities

Authors: Xing Li, Kaida Liu, Haohan Fang, Zirong Liu, Yuchen Tang, Ping Dai
Journal: APL Bioengineering
Year: 2024

A theoretical study on evaluating brain tumor changes in tumor treating fields therapy by impedance detection

Authors: Xing Li, Kaida Liu, Haohan Fang, Rongzi Liu, Wei Gao, Ping Dai
Journal: Frontiers in Oncology
Year: 2024

Prof. Maoyi Xu | Thoracic Neoplasms | Best Researcher Award

Prof. Maoyi Xu | Thoracic Neoplasms | Best Researcher Award

The Affiliated Hospital of Jiaxing University | China

AUTHOR PROFILE

Scopus

🏫 EARLY ACADEMIC PURSUITS

Maoyi Xu began his academic journey with a Bachelor of Medicine in Clinical Medicine at Jiaxing University (2009–2014). During these formative years, Xu developed a strong foundation in medical sciences and clinical applications, showcasing a keen interest in oncology. This passion led him to pursue advanced education, obtaining a Master of Medicine in Oncology from Dalian Medical University, China, in 2017. His graduate studies were characterized by rigorous research and hands-on training, laying the groundwork for his future career in oncology.

💼 PROFESSIONAL ENDEAVORS

Maoyi Xu’s professional career began with a pivotal role at the Department of Radiotherapy Oncology, Zhuji People’s Hospital of Zhejiang Province (2017–2019), affiliated with Wenzhou Medical University. Here, he honed his skills in radiotherapy and gained invaluable experience treating cancer patients.
In 2019, Xu transitioned to the Department of Oncology at the First Affiliated Hospital of Jiaxing University, where he continues to work. His role involves comprehensive patient care, cutting-edge research, and contributions to the hospital’s oncology department’s growth.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON THORACIC NEOPLASMS

Xu has focused his research on innovative cancer treatment strategies, particularly in radiotherapy and targeted oncology treatments. He is committed to improving patient outcomes by integrating the latest advancements in oncology into clinical practice. Xu’s research bridges the gap between theory and application, enhancing therapeutic methodologies to benefit patients.

🌟 IMPACT AND INFLUENCE

Through his work, Xu has positively influenced oncology practices within Zhejiang Province and beyond. His contributions have led to advancements in radiotherapy techniques and improved patient care protocols. Xu is also a mentor to young professionals, fostering a culture of learning and collaboration.

📊 ACADEMIC CITATIONS

Although Xu’s academic citations are in development, his publications have started to gain recognition in medical circles. His research papers focus on innovative radiotherapy approaches and patient-centered care strategies. These contributions are adding value to the field of oncology.

🏅 LEGACY AND FUTURE CONTRIBUTIONS

Maoyi Xu is poised to leave a lasting legacy as a dedicated oncologist and researcher. He envisions a future where his contributions will significantly impact cancer treatment practices and policies, particularly in China. Xu aims to pioneer new research initiatives, foster interdisciplinary collaboration, and improve cancer care at both the local and global levels.

OTHER IMPORTANT TOPICS

🌐 COMMUNITY ENGAGEMENT

Xu actively participates in health awareness programs, aiming to educate the public about early cancer detection and prevention.

📚 CONTINUOUS LEARNING

A proponent of lifelong learning, Xu frequently attends conferences and workshops, staying updated on the latest developments in oncology.

🧬 INNOVATIVE PRACTICES

Xu is exploring personalized medicine and genetic research in oncology, positioning himself at the forefront of emerging trends.

📝 CONCLUSION

Maoyi Xu’s journey from an aspiring medical student to a dedicated oncologist and researcher exemplifies a commitment to excellence and innovation in the field of oncology. His academic pursuits laid a solid foundation for his professional growth, while his clinical and research contributions continue to impact cancer treatment and patient care.

 

📊🔬NOTABLE PUBLICATION:
  • The combination of decitabine and aspirin inhibits tumor growth and metastasis in non-small cell lung cancer
    • Authors: Xu, M., Song, B., Yang, X., Li, N.
    • Journal: Journal of International Medical Research
    • Year: 2022

 

  • Exosomal miR-122-3p represses the growth and metastasis of MCF-7/ADR cells by targeting GRK4-mediated activation of the Wnt/β-catenin pathway
    • Authors: Song, B., Hou, G., Xu, M., Chen, M.
    • Journal: Cellular Signalling
    • Year: 2024

 

  • Zoledronic acid inhibits the bone metastasis of breast cancer by repressing exosome-loaded DKK1
    • Authors: Song, B.B., Xu, M.Y., Xu, X.F., Li, X., Chen, M.
    • Journal: Bangladesh Journal of Pharmacology
    • Year: 2022

 

  • Association between the Khorana risk score and all-cause mortality in Japanese patients with gastric and colorectal cancer: A retrospective cohort study
    • Authors: Zhang, Y.-F., Wang, G.-D., Huang, M.-G., Si, J., Xu, M.-Y.
    • Journal: World Journal of Gastrointestinal Oncology
    • Year: 2023

 

  • β-elemene inhibits radiation and hypoxia-induced macrophages infiltration via Prx-1/NF-κB/HIF-1α signaling pathway
    • Authors: Yu, X., Li, Z., Zhang, Y., Zou, K., Zou, L.
    • Journal: OncoTargets and Therapy
    • Year: 2019